Insulet (Nasdaq:PODD) announced today that it acquired assets related to Bigfoot Biomedical’s pump-based automated insulin delivery technologies.
Acton, Massachusetts-based Insulet paid $25 million to acquire the AID assets. These include certain Bigfoot patents related to pumps that may be used for AID therapy. Insulet already develops its own AID technology with its Omnipod platform.
Get the full story at our sister site, Drug Delivery Business News.
[Image courtesy of Walmart]
After a banner year for diabetes technology in 2022, there’s still plenty to look forward to in 2023.Throughout 2022, we saw a wide range of advancements in diabetes technology. We saw launches for next-generation technologies, exciting clinical trial results, and rumored spinouts and acquisitions.
You can read all about the biggest diabetes stories of 2022 here.
There’s plenty to look forward to in the diabetes space in the months ahead. Here are a few things worth keeping an eye on.
CMS decision could benefit CGMsIn October, The Centers for Medicare and Medicaid Services (CMS) published a new local coverage determination (LCD). That LCD modified coverage criteria for continuous glucose monitors (CGMs). The modification includes people with diabetes who receive insulin treatment or have a history of problematic hypoglycemia.
Analysts suggested at the time …
Throughout 2022, we saw a wide range of advancements in diabetes technology. We saw launches for next-generation technologies, exciting clinical trial results, rumored spinouts and acquisitions and more.
You can read all about the biggest diabetes stories of 2022 here.
As we embark on a new year in 2023, there’s still plenty to look forward to in the diabetes space. Here are a few things worth keeping an eye on.
CMS decision could benefit CGMsIn October, The Centers for Medicare and Medicaid Services (CMS) published a new local coverage determination (LCD). That LCD modified coverage criteria for continuous glucose monitors (CGMs). The modification includes people with diabetes who receive insulin treatment or have a history of problematic hypoglycemia.
Analysts suggested at the time that the decision marked a win for …
The MassDevice MedTech 100 Index, which includes stocks of the world’s largest medical device companies, reflects the performance of many in the medtech space.
In a tough year for a lot of businesses, the Index wasn’t immune to struggles. Overall, it dropped 27.3% from this time last year. That compares to a 19.7% drop for the S&P 500 and an 8.9% dip for the Dow Jones Industrial Average.
Some businesses, though, powered through the supply chain- and inflation-related woes to see their stock rise from this time last year. Others weren’t so lucky. Here are some of the biggest gainers and losers — selected from the MedTech 100 Index — of 2022.
Biggest gainers BD — $245.27 to $254.97 — Up 4%While BD (NYSE:BDX) didn’t have the most significant growth, its stock remains in a …
Some companies picked up major regulatory nods. Others experienced major regulatory setbacks.
Partnerships were formed and ended, while mergers and acquisitions came and went. There were many stories to choose from, but here are 10 big ones that stood out:
Dexcom G7 receives FDA clearanceThe long-awaited regulatory nod for Dexcom’s next-generation continuous glucose monitor (CGM) finally came in December.
Some suggested that San Diego-based Dexcom may pick up clearance as soon as summer 2022. However, a software change recommended by the FDA, plus COVID-19-related backlog, delayed proceedings.
Dexcom COO Ja…
Alpuche informed the company of his decision to retire on Dec. 13. His retirement takes effect on Dec. 31, 2022.
Get the full story at our sister site, Drug Delivery Business News.
Insulet recently issued a voluntary global safety notice to warn about battery problems. The Omnipod Dash is Insulet’s previous-generation insulin pump. The company since launched its FDA-cleared and CE-marked Omnipod 5 next-generation automated insulin delivery system.
The Omnipod Dash includes a Personal Diabetes Manager (PDM) — a locked-down Android mobile device with features similar to a smartphone that controls the Pod delivering insulin. The FDA says Insulet has received Insulet 455 complaints involving these battery issues, including three fires. There have been no reports of injuries or deaths.
Reported problems include battery swelling, fluid leakage…
Acton, Massachusetts-based Insulet’s correction relates to an issue with the Omnipod 5 controller’s charging port and cable. The correction does not impact the Omnipod 5 pod, the previous-generation Omnipod Dash and Omnipod, or compatible Android smartphone devices with the Omnipod 5 app installed.
Get the full story at our sister site, Drug Delivery Business News.
Insulet (Nasdaq:PODD) shares ticked up after hours today on third-quarter results that came in ahead of the consensus forecast.
Shares of PODD rose 8.1% at $276 apiece after the market closed today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the day down 3.8%.
The Acton, Massachusetts-based company posted a $5.2 million loss for the quarter. That equals 8¢ per share on sales of $340.8 million for the three months ended Sept. 30, 2022.
Get the full story at our sister site, Drug Delivery Business News.
The Omnipod Dash is Insulet’s previous-generation insulin pump. The company since launched its FDA-cleared and CE-marked Omnipod 5 next-generation automated insulin delivery system. Insulet’s notice went out to current and past users of the Omnipod Dash insulin management system.
According to the notice in Europe on Nov. 2 and a news release posted on Nov. 4, the warning relates to the Omnipod Dash Personal Diabetes Manager (PDM) and its battery. Insulet said there have been 50 complaints — but no reports of serious injury or death — related to the Omnipod Dash PDM battery issues. The notice does not apply to the Omnipod Dash pods or the Omnipod i…
As we enter November, we enter National Diabetes Awareness Month. A number of diabetes technology developers plan to mark that in a special way.
Dexcom (Nasdaq:DXCM), Insulet (Nasdaq:PODD) and Embecta (Nasdaq:EMBC) all announced their plans to celebrate.
Last year, a handful of companies marked the month — which includes World Diabetes Day (Nov. 14) — in a series of ways. Here’s how they’re doing it this year.
Get the full story at our sister site, Drug Delivery Business News.
Insulet can now market Omnipod 5 in Europe for individuals 2 years and older with type 1 diabetes. Acton, Massachusetts–based Insulet said it represents the first CE-marked tubeless hybrid closed loop system
The latest-generation Omnipod 5 became the first tubeless, wearable automated insulin delivery system cleared for marketing in the U.S. in January. That clearance covered individuals 6 years of age and older. Last month, the FDA cleared Omnipod 5 for individuals aged 2 and older.
Get the full story at our sister site, Drug Delivery Business News.